With the advent of the immunotherapy era in oncology, researchers have held great expectations for immunotherapy-based adjuvant treatments in HCC. The IMbrave 050 study, as the first global trial to ...

Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), ...

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020, according to the World ...

Immunotherapy has revolutionised the treatment of advanced hepatocellular carcinoma, starting with atezolizumab–bevacizumab superseding sorafenib in the first line. But how have other areas of care ...

Transplantation combined with immunotherapy to cure liver cancer. Hepatocellular carcinoma (HCC) is the most common type of liver cancer in Switzerland and worldwide. Immunotherap ...

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option after NICE gave the nod to NHS funding of Roche ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive officer and co-founder of Teclison ...